"5'-Nucleotidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein enzyme present in various organs and in many cells. The enzyme catalyzes the hydrolysis of a 5'-ribonucleotide to a ribonucleoside and orthophosphate in the presence of water. It is cation-dependent and exists in a membrane-bound and soluble form. EC 3.1.3.5.
Descriptor ID |
D015720
|
MeSH Number(s) |
D08.811.277.352.650.600.600
|
Concept/Terms |
5'-Nucleotidase- 5'-Nucleotidase
- 5' Nucleotidase
- 5'-Nucleotidase Phosphoribolase
- 5' Nucleotidase Phosphoribolase
- Adenylate Phosphatase
- AMP Phosphatase
- Cytidylate Phosphatase
- Ecto-5'-Nucleotidase
- Ecto 5' Nucleotidase
- IMP Nucleotidase
- CD73 Antigens
- IMPase
- Inosinate Phosphatase
- Pyrimidine 5'-Nucleotidase
- Pyrimidine 5' Nucleotidase
- Thymidine Phosphatase
- Uridylate 5'-Nucleotidase
- Uridylate 5' Nucleotidase
- Antigen, CD73
- CD73 Antigen
- Antigens, CD73
- 5'-AMP Nucleotidase
- 5' AMP Nucleotidase
- IMP Phosphatase
|
Below are MeSH descriptors whose meaning is more general than "5'-Nucleotidase".
Below are MeSH descriptors whose meaning is more specific than "5'-Nucleotidase".
This graph shows the total number of publications written about "5'-Nucleotidase" by people in this website by year, and whether "5'-Nucleotidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2007 | 0 | 2 | 2 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 3 | 0 | 3 |
2013 | 1 | 2 | 3 |
2015 | 0 | 1 | 1 |
2016 | 3 | 0 | 3 |
2018 | 2 | 1 | 3 |
2019 | 1 | 0 | 1 |
2020 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "5'-Nucleotidase" by people in Profiles.
-
CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Cancer Res. 2023 04 04; 83(7):1111-1127.
-
Second-Generation CD73 Inhibitors Based on a 4,6-Biaryl-2-thiopyridine Scaffold. ChemMedChem. 2023 04 03; 18(7):e202200594.
-
Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia. Cancer Discov. 2022 11 02; 12(11):2646-2665.
-
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1965-1976.
-
4-Substituted-1,2,3-triazolo nucleotide analogues as CD73 inhibitors, their synthesis, in vitro screening, kinetic and in silico studies. Bioorg Chem. 2021 02; 107:104577.
-
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).
-
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
-
Synthesis of Substituted 5'-Aminoadenosine Derivatives and Evaluation of Their Inhibitory Potential toward CD73. ChemMedChem. 2019 08 06; 14(15):1431-1443.
-
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. Haematologica. 2018 12; 103(12):2069-2078.
-
Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2018 05; 77(5):714-719.